Literature DB >> 16481508

TLR2 is necessary to inflammatory response in Coxiella burnetii infection.

Soraya Meghari1, Amélie Honstettre, Hubert Lepidi, Bernardt Ryffel, Didier Raoult, Jean-Louis Mege.   

Abstract

The resolution of Q fever, a zoonosis caused by Coxiella burnetii, depends on efficient innate and adaptive immune responses. Such responses are influenced by Toll-like receptors (TLRs). TLR4 is involved only in part in immune responses against C. burnetii, suggesting a role for TLR2. We investigated C. burnetii infection in wild-type and TLR2(-/-) mice. C. burnetii organisms were similarly eliminated by wild-type and TLR2(-/-) mice. In contrast, the formation of granulomas, a marker for efficient cell-mediated immunity, was markedly impaired. These results show that TLR2 is required for inflammatory and immune response to C. burnetii, but is dispensable for bacterial clearance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16481508     DOI: 10.1196/annals.1355.025

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  12 in total

1.  Development of an Ex Vivo Tissue Platform To Study the Human Lung Response to Coxiella burnetii.

Authors:  Joseph G Graham; Caylin G Winchell; Richard C Kurten; Daniel E Voth
Journal:  Infect Immun       Date:  2016-04-22       Impact factor: 3.441

Review 2.  From Q Fever to Coxiella burnetii Infection: a Paradigm Change.

Authors:  Carole Eldin; Cléa Mélenotte; Oleg Mediannikov; Eric Ghigo; Matthieu Million; Sophie Edouard; Jean-Louis Mege; Max Maurin; Didier Raoult
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

3.  Analysis of the Caenorhabditis elegans innate immune response to Coxiella burnetii.

Authors:  James M Battisti; Lance A Watson; Myo T Naung; Adam M Drobish; Ekaterina Voronina; Michael F Minnick
Journal:  Innate Immun       Date:  2016-11-24       Impact factor: 2.680

4.  Roles of Toll-Like Receptor 2 (TLR2), TLR4, and MyD88 during Pulmonary Coxiella burnetii Infection.

Authors:  Andrew G Ramstead; Amanda Robison; Anne Blackwell; Maria Jerome; Brett Freedman; Kirk J Lubick; Jodi F Hedges; Mark A Jutila
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441

5.  Natural Exposure- and Vaccination-Induced Profiles of Ex Vivo Whole Blood Cytokine Responses to Coxiella burnetii.

Authors:  Susan Raju Paul; Anja Scholzen; Ghazel Mukhtar; Stephanie Wilkinson; Peter Hobson; Richard K Dzeng; Jennifer Evans; Jennifer Robson; Rowland Cobbold; Stephen Graves; Mark C Poznansky; Anja Garritsen; Ann E Sluder
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

6.  To die or not to die: Programmed cell death responses and their interactions with Coxiella burnetii infection.

Authors:  Chelsea A Osbron; Alan G Goodman
Journal:  Mol Microbiol       Date:  2022-02-02       Impact factor: 3.979

7.  Attenuated Coxiella burnetii phase II causes a febrile response in gamma interferon knockout and Toll-like receptor 2 knockout mice and protects against reinfection.

Authors:  Javier Ochoa-Repáraz; Jami Sentissi; Theresa Trunkle; Carol Riccardi; David W Pascual
Journal:  Infect Immun       Date:  2007-09-24       Impact factor: 3.441

8.  Coxiella burnetii Infects Primary Bovine Macrophages and Limits Their Host Cell Response.

Authors:  Katharina Sobotta; Kirstin Hillarius; Marvin Mager; Katharina Kerner; Carsten Heydel; Christian Menge
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

9.  Coxiella burnetii Employs the Dot/Icm Type IV Secretion System to Modulate Host NF-κB/RelA Activation.

Authors:  Saugata Mahapatra; Brandi Gallaher; Sydni Caet Smith; Joseph G Graham; Daniel E Voth; Edward I Shaw
Journal:  Front Cell Infect Microbiol       Date:  2016-12-19       Impact factor: 5.293

10.  The uptake of apoptotic cells drives Coxiella burnetii replication and macrophage polarization: a model for Q fever endocarditis.

Authors:  Marie Benoit; Eric Ghigo; Christian Capo; Didier Raoult; Jean-Louis Mege
Journal:  PLoS Pathog       Date:  2008-05-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.